Format

Send to

Choose Destination
Clin Genitourin Cancer. 2019 Oct;17(5):373-379.e4. doi: 10.1016/j.clgc.2019.06.011. Epub 2019 Jun 26.

Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series.

Author information

1
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Urology, Ludwig-Maximilians University, Munich, Germany.
2
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
3
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
4
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL.
5
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
6
Department of Urology, Ludwig-Maximilians University, Munich, Germany.
7
Molecular Oncology, Department of Medicine, Siteman Cancer Center, Washington University, St Louis, MO.
8
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
9
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: hakimia@mskcc.org.

Abstract

BACKGROUND:

The purpose of the study was to evaluate clinical features and prognostic factors in a large single institutional cohort of chromophobe renal cell carcinoma (ChRCC) patients for identification of tumors with the highest metastatic potential.

PATIENTS AND METHODS:

Clinicopathological parameters of all patients with ChRCC diagnosed and surgically treated at Memorial Sloan Kettering Cancer Center between 1990 and 2016 were identified and compared with patients treated for clear-cell renal cell carcinoma (ccRCC) in the same study period using Wilcoxon test for continuous variables and Fisher exact test for categorical variables. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan-Meier method, log rank test, and Cox proportional hazards regression.

RESULTS:

Four hundred ninety-six patients with ChRCC (10-year RFS, 91.7% and OS, 82.1%) and 3312 patients with ccRCC (10-year RFS, 79.4% and OS, 63.6%) were included in the analysis. Patients with ChRCC were younger (median 59 vs. 61 years; P = .0015), less frequently male (54.8% vs. 66.3%; P < .0001), showed more favorable T stages (T1-2 in 78% vs. 67%; P < .0001) and less frequent sarcomatoid differentiation (1.2 % vs. 4%; P = .0008) and showed lower rates of metastatic development compared with ccRCC patients. Larger tumor size, sarcomatoid differentiation, and higher T-stage are significantly associated with adverse RFS and OS in chromophobe tumors.

CONCLUSION:

ChRCC is more commonly diagnosed in female and younger patients and is associated with a more favorable clinical outcome and a lower propensity for metastatic development than ccRCC. Larger tumors and sarcomatoid differentiation of ChRCC might be considered as risk factors for metastatic development.

KEYWORDS:

Clear-cell renal cell carcinoma; Clinical outcome; Non–clear-cell renal cell carcinoma; Retrospective analysis; Sarcomatoid differentiation

PMID:
31326335
PMCID:
PMC6790280
[Available on 2020-10-01]
DOI:
10.1016/j.clgc.2019.06.011

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center